A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)

Invest New Drugs. 2008 Apr;26(2):193-4. doi: 10.1007/s10637-007-9104-1. Epub 2007 Dec 4.

Authors

J J Knox¹, X E Chen, R Feld, M Nematollahi, R Cheiken, G Pond, J A Zwiebel, S Gill, M Moore

Affiliation

¹ Princess Margaret Hospital Phase II Consortium, and University Health Network, University of Toronto, Toronto, Ontario, Canada. [email protected]

PMID: 18060598
DOI: 10.1007/s10637-007-9104-1

No abstract available

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*
Dose-Response Relationship, Drug
Doxorubicin / administration & dosage
Female
Hematologic Diseases / chemically induced
Humans
Liver Neoplasms / drug therapy*
Male
Middle Aged
Proto-Oncogene Proteins c-bcl-2 / metabolism
Thionucleotides / administration & dosage
Treatment Outcome

Substances

Proto-Oncogene Proteins c-bcl-2
Thionucleotides
Doxorubicin
oblimersen